Member Info for WengerOut

McGuire is a defensive footballer recently bought by Manchester United for £80m while we are valued at a measly £15m, ludicrous the valuations of both.

Of course title should read 6 Amur Minerals

For the value of 6 Amur Minerals you could buy Harry McGuire. World’s gone mad!

“Bloomberg New Energy Finance forecasts that demand for nickel will multiply 16 times by 2030, and half of that is expected to go into batteries.”

There are buys on the NEX market, with the cut spread we are actually over 2p

My 2 beauties that will help me in my retirement, both 10 plus baggers!

Early August means next week by the latest, feeling the tingle in my toes as I speak, not long now. Finally about to start on the journey north.

Me too, no one is having my shares, these will be the icing on my forthcoming pension. Keep the faith, nearly there.

A lot of those sells are buys anyway, I know as one of them is mine. Not long to wait now, Dave will deliver and hopefully we'll lose some of the miserable moaners on here who keep repeating the same thing over and over again.

I believe the Farm Out will happen more mid June, if there was a danger it was going to run to late June then Dave would have said “June / July”

Your amur minerals second partner below High-tech products are highly competitive in the global market. The output of composite plates and the market share of super-strong offshore steel reached the first in the country; in the complicated foreign trade environment, the export of nickel-based steels will became prominent and became the first steel enterprise in China to import/export high-end nickel-based steels in batches. Standard low-temperature structural steel fills the domestic gap and supplies tens of millions of dollars to the Russian Amur Minerals project.

LeeChang - Amur Minerals CEO interview was not published because of the updated MOD with Jinchuan. New MOD only published on 2019-05-04,evidence below Google out below, CEO was interviewed and according to rumours in China he did accidentally told about nda with Jinchuan and because of it the interview was removed from brr mediauk website. 20 May 2019 Robin Young, CEO, at the @Invest in mining conference in London being interviewed by @brr_mediauk discussing Amur's Kun Manie project following the Company's significant PFS milestone. And following- Amur Mining and Jinchuan Group cooperate to develop nickel sulfide mine 2019-05-04 01:12 Xiaobian: Webmaster Amur Minerals Corporation and China's largest nickel producer Jinchuan Group signed to jointly develop a nickel sulphide project. The Memorandum of Understanding (MOU) involves engineering, design, procurement, and construction of both parties, but the first phase of the detailed investigation phase is carried out by Jinchuan. One of the world's largest sulphide deposits in the Kun-Manie nickel deposit of Amur, located in the Far East of Russia, not far from the Chinese border. “We are pleased to sign a Memorandum of Understanding, which will lead us to maintain long-term cooperation with the world-famous company Jinchuan Group in the nickel industry,” said Amur CEO Robin Young. http : // www .awufengfangguan.com/wufengfangguanziliao-3/2303.html

Or ring Robin young on his mobile which is at the bottom of each RNS +7 (4212) 75 56 15.

Avacta plans for exciting cancer immunotherapy (won't post link as won't work on here)

11:21 03 Jun 2019

The group's technology releases chemo directly inside a tumour without exposing the whole body to toxins.

Avacta Group PLC (LON:AVCT) has said it will go to clinic “well ahead of original plans” with a drug candidate that combines its binding protein technology with chemotherapy.

The group's tumour microenvironment activated drug conjugates (TMAC) are a ground-breaking new form of cancer immunotherapy.

Co-invented with Tufts University Medical School of the US, TMAC brings together Avacta’s Affimers with chemotherapies in a single drug using a linker that is designed to only release the chemo in the tumour.

The plan is to gain permission for phase I trial in early 2020 to test the potential new treatment in people with certain types of solid tumours.

Major milestone

The company called the first-in-man study “a major de-risking milestone for the programme”.

"What is so attractive about Avacta's Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same level of the chemo-toxin,” said chief executive Alastair Smith.

“Whilst immunotherapies offer great promise for cancer patients, it is well established that only a relatively small sub-group of patients see durable responses to single immune checkpoint therapies. Avacta is directly addressing this urgent clinical need with its novel Affimer TMAC and bispecific programmes,” he added.

Targeted approach

In order to test the TMAC linker in humans for the first time, a chemo treatment called doxorubicin will be modified with the Avacta linker, rendering it inactive and harmless until the linker is split in the tumour, releasing an active cancer-killing agent.

Doxorubicin has well-documented safety issues limiting its dosing, and also putting a cap on the number patients that can be treated with it.

The shares rose 8% on the news, to change hands for 32.12p. Broker finnCap’s target price is 125p.

Analyst Mark Brewer told investors: “Not only is this testing of the TMAC linker well ahead of original plans, but it potentially creates additional sources of non-dilutive funding from licensing the linker to create effective chemotherapeutic pro-drugs that are currently limited by dose-limiting systemic toxicities.

“Proving the enzyme-sensitive linker works in humans also increases the prospect of licensing the Affimer TMAC platform before clinical data are generated from its first Affimer TMAC.”

Avacta's TMAC linker has been shown to increase the maximum tolerated dose by a factor of six in a pre-clinical study in mice.

Maybe the start of the newsflow that we were promised.

Give us LOL

https:// www.*************.net/ceo-qa-with-alastair-smith-at-avacta-group-plc-lonavct/

https:/ /www.*************.net/ceo-qa-with-alastair-smith-at-avacta-group-plc-lonavct/

Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year

11:40 09 Apr 2019 The first Affimer-based therapeutic is PD-L1 is a potential cancer treatment that helps the immune system to identify and attack cancer cells

Affimers have both therapeutic and non-therapeutic uses

Avacta Group PLC (LON:AVCT) remains on track to begin a Phase I clinical trial of its first Affimer therapeutic candidate next year.

Affimers are small, engineered proteins that are capable of binding specific molecular targets, in a similar way to antibodies.

READ: Avacta says partner Moderna takes collaboration to next level

The proteins are smaller, quicker to manufacture and easier to format than antibodies, but they maintain antibody-like biologic activity when binding a target.

Avacta thinks the technology has both therapeutic and non-therapeutic applications.

The AIM company is already using Affimers to develop various potential cancer treatments, while other companies pay to use the technology in their research and diagnostics.

Avacta has selected a PD-L1 inhibitor as the first Affimer-based potential cancer therapeutic that it is taking through the clinic.

PD-L1 is a checkpoint protein that essentially provides a cloak for the cancer cells, helping them to evade detection by the immune system.

Start dosing in Q4 2020

The company is soon to start manufacturing its PD-L1 inhibitor – called AVA004-251 – which will then allow it to file a clinical trial application, asking regulators to let it test the drug on humans.

That filing is expected to happen in late 2020 and the plan is to start dosing the first patients in a Phase I dose escalation study in the final quarter of next year.

“The group remains focused on the key objective of first-time-in-human data for the Affimer therapeutic programme and growing a profitable Affimer reagents business,” said chief executive Alastair Smith.

“First-time-in-human data is a significant value inflection point for the technology and a major de-risking point from a deal-making perspective. The group remains on track, to a tight schedule, to dose first patients in late 2020.”

Plenty of cash in the bank

For the six months ended 31 January, Avacta recorded revenues of £1.0mln (H1 18: £1.5mln), although the new licensing deal with LG Chem will boost second-half numbers.

Unsurprisingly, R&D costs rose to £2.4mln (H1 18: £1.5mln) in the period, which meant operating losses climbed to £5.9mln (H1 18: £4.5mln).

Thanks to an £11.6mln fundraise in August, cash on hand totalled £11.8mln at the end of January (H1 18: £5.2mln).

In a note to clients, analysts at ‘house’ broker finnCap commented: “Significant progress continues to be made in non-therapeutic applications that include at least two in-house diagnostic assay development programmes with further licence

https:// www.proactiveinvestors.co.uk/companies/news/218211/avacta-well-cashed-and-on-track-to-begin-clinical-trial-of-first-affimer-therapeutic-next-year-218211.html